ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Carboplatin

Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.

Drug pageCarboplatin: every studyMany companies study it; this page follows only the 89 they lead. All 1,229 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 24, 200989 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only300 open or runningphase 4since Nov 24, 2009Apr 30, 2002none ahead
Bristol-Myers Squibbits history only140 open or runningphase 4since May 28, 2014Sep 13, 2001none ahead
Sanofi70 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Instituteits history only31 open or runningphase 2since Nov 2, 2005Nov 2, 2005none ahead
Swedish Orphan Biovitrumits history only30 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
AGO Researchits history only20 open or runningphase 3since Apr 16, 2013Apr 16, 2013none ahead
CarTheraits history only21 open or runningphase 3since Jun 5, 2023Nov 13, 2018Jan 28, 2028phase 3 · NCT05902169
Eisaiits history only20 open or runningphase 3since Dec 31, 2002Dec 31, 2002none ahead
InSightecits history only20 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Ionis Pharmaceuticalsits history only20 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Daiichi Sankyo, AstraZeneca, Merck, Parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, Novotech (Australia) Pty, WuXi CDS Clinical Research (Shanghai), Valerio Therapeutics, Ortho Biotech, Tibotec Pharmaceutical and Medarex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2001First study: phase 3 study in Breast NeoplasmsFirst studyNCT00021255 · 3,222 enrolled · United States, Argentina, Australia and more
  2. Oct 14, 2003Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00071188 · United States, Finland, France and more
  3. Jul 13, 2004Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00087802 · 383 enrolled · United States
  4. Nov 23, 2005Phase 2 study in Lung NeoplasmsNCT00258739 · 140 enrolled · Spain
  5. Aug 16, 2006Phase 2 study in Breast NeoplasmsNCT00365365 · 214 enrolled · United States
  6. Sep 18, 2008Phase 1 study in NeoplasmsNCT00756847 · 52 enrolled · United States
  7. Oct 13, 2008Phase 2 study in Lung NeoplasmsNCT00826852 · 49 enrolled · Turkey

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00826852Lung Neoplasms · Turkey2CompletedJul 200949
NCT00756847Neoplasms · United States1CompletedMay 201252
NCT00365365Breast Neoplasms · United States2CompletedOct 2011214
NCT00258739Lung Neoplasms · Spain2CompletedSep 2007140
NCT00087802Carcinoma, Non-Small-Cell Lung · United States3CompletedMay 2007383
NCT00071188Carcinoma, Non-Small-Cell Lung · United States, Finland, France and more2CompletedOct 2007
NCT00021255Breast Neoplasms · United States, Argentina, Australia and more3CompletedDec 20143,222

How it is read

Names in the registry

  • “Carboplatin”, 110 entries
  • “carboplatin”, 38 entries
  • “Pemetrexed/Carboplatin”, 2 entries
  • “CARBOPLATIN”, 2 entries
  • “Carboplatin/Paclitaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.